Re: moxa1

Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Reply New Message

Prev Message Back To Forum Threaded View Next Message

milestone

Rank: President [?]

Points: 18650 [?]

Votes: 158 Score: 3.4 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: moxa1

in response to

Re: Why did the reporting for this quarter end on 1/31/2008?

moxa1

posted on Apr 15, 2008 08:29AM

milestone - Forgive me if you've already posted this, but if you have any further thoughts on whether or not the entire settlement from the J2.5 was contained in the 10Q would be interesting for some of us to peruse. Thanks.

I believe that any payments due from the J2.5 during the period of the 10Q were fully accounted for, that is not to say that I am satisfied that Judge Ward is retaining supervision of a MOU which could be so quickly fulfilled.

The "with prejudice" ruling means that TPL/PTSC can not litigate the same patents again with the J2.5 as defendants. Had there been a simple license agreement, there would be no need of a MOU. Logic therefore dictates additional terms which, given that the J2.5 can't be sued again for infringement on the '336/'148, are favorable to PTSC/TPL.

In conclusion, I do not believe that the J2.5 have made a full and final settlement.